Climb Bio director Andrew Levin resigns; Breanna O'Reilly elected to board

Climb Bio, Inc.

Andrew Levin resigned from the board effective June 29, 2026.
Breanna O'Reilly, Ph.D., elected as director effective June 29, 2026.
O'Reilly received option for 70,284 shares at $13.36, vesting over 3 years.
O'Reilly to receive $40,000 annual cash retainer and annual equity grants.
No family relationships or related-party transactions with O'Reilly.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.